Aspirin resistance in patients with coronary artery disease  by Walton, Brian L. et al.
JACC March 19,2003 ABSTRACTS - Myocardial Ischemia and Infarction 335A 
POSTER SESSION 
1026 Safety and Efficacy of Drug Therapy of 
Coronary Artery Disease 
Sunday, March 30, 2003, NoonQ:OO p.m. 
McCormick Place, Hall A 
Presentation Hour: Noon-l :00 p.m. 
1026-100 Effect of Roxithromycin on Clinical Cardiovascular 
Events in Patients Undergoing Coronary Angioplasty 
Jan Kaehler. Antje Haar, Klaus-Peter Schaps, Marion Carstensen. Ralf Koester, Wolfram 
Terms, Thomas Meinertz. University Hospital Hamburg, Hamburg, Germany, Celle 
General Hospital, Celle, Germany 
Background: Seropositivity for chlamydia pneumoniae has been associated with coro- 
nary artery disease, but results of interventional studies with antibiotics have been con- 
tradictory. We therefore investigated whether clinical cardiovascular events in patients 
undergoing coronary angioplasty can be reduced by medication with roxithromycin. 
Methods: 327 consecutive patients undergoing coronary angioplasty were randomized to 
roxithromycin 300 mgld for 6 weeks or placebo regardless of antibody titers. The primary 
clinical end point included cardiovascular death, nonfatal infarction (Ml) and symptomatic 
restenosis at 1 year. indication for angioplasty was stable angina in 51/47% of patients 
(roxithromycinlplacebo). unstable angina in 43144% and prognostic in 6g% of patients. 
Results: Treatment groups were balanced for age, BMI and risk factors, and roxithromy- 
tin was well tolerated. During the trial period of 1 year, 36 endpoints occurred (cardiovas- 
cular death, 1; MI, 4; and symptomatic restenosis, 31) with 20 events in the 
roxithromycin group and 16 in the placebo group, n.s.. When analyzed for the 3 indica- 
tion groups, there was a trend towards more events in the unstable angina group receiv- 
ing roxithromycin, but ho significant differences could be detected in any of the groups. 
lschemic stroke occurred in 3 roxithromycin VS. 0 placebo patients, hs.. 
Conclusion: The results of our study suggest that antibiotic therapy with roxithromycin in 
unselected patients undergoing coronary angioplasty is not associated with a reduction 
of clinical cardiovascular events. However, this does not exclude positive effects of anti- 
biotics in subgroups such as patients with high antibody titers against chlamydia pneu- 
moniae. 
1026-101 Low-Molecular-Weight Heparin Alone and With Ilb/llla 
Inhibitors in Patients With Renal Failure and Non-ST 
Elevation Acute Coronary Syndromes: Insights From 
the Global Registry of Acute Coronary Events 
Jean-Philippe Collet Giancarlo Agnelli, Frans J. Van de Wed, David Brieger, Enrique P. 
Gurfinkel, Jose Lopez-Sendon, Neelam Gowda, Gilles Montalescot, oh behalf of the 
GRACE Investigators, Hopital Pitie-Salpetriere, Paris, France, University of Perugia - 
Ospedale Silvestrini, Perugia, Italy 
Background: LMWH is a reference treatment for NSTE-ACS. Data are lacking in 
pahents (pts) with moderate (creatinine clearance [CC] >30-GO mUmin, MRF) & severe 
(40. SRF) renal farlure. 
Hypothesis: LMWH alone or with llblllla Inhibitors provides greater benefit than unfrac- 
tionated heparin (UFH) irrespective of renal status. 
Methods: Data were utilized from 13,325 NSTE-ACS pts. 
Results: Pts with MRF (n=3,049) or SRF (n=816) were at higher risk of adverse out- 
comes than normal renal function (NRF) pts as reflected by ah increased prevalence of 
elderly pts, diabetes, heart failure, ST depression & positive troponin. Decreasing CC 
was an independent predictor of death at 30 d (OR 1.6/30 mUmin) 5 hospital major 
bleeding (OR 1.3130 mUmin). While 50% of pts were treated with LMWH (64% enox- 
aparin), there was significantly less use of LMWH+llb/llla in MRF (15%) & SRF (12%) 
than NRF pts (21%). The magnitude of benefit of LMWH alone over UFH alone was sim- 
ilar irrespective of renal status (Table). Use of LMWH alone was ah independent predic- 
tor of survival (OR 0.57) and lees bleeding (OR 0.54). Bleeding rates were lower with 
LMWH+llb/llla compared to UFH+llb/llla irrespective of renal status. UFH+llb/llla was ah 
independent predictor of bleeding (OR 2.12). 
CC (mumin) <30 3060 >&I P-value 
Death 
UFH (%) 43 (26) 66 (12) 47 (5) <O.OOOl 
LMWH (%) 36 (22) 48 (8) 31 (3) <0.0901 
LMWH vs UFH (P-value) 0.30 0.018 0.015 
Major Bleeding 
UFH (%) 18 (8) 35 (4) 3’ (2) <0.0001 
LMWH (%) 13 (5) f5(2) 5 (1) <0.0001 
UFH vs LMWH (P-value) 0.27 0.0008 0.002 
Conclusion: In this observational study renal failure is aesocrated with ah excess of car- 
diovascular death & major bleeding. Bleeding complications are more frequent 5 severe, 
& outcomes apparently worse, rn patients treated with UFH than with those oh LMWH. 
1026- 102 Efficacy and Safety of a Chronotherapeutic Graded- 
Release Diltiazem Hydrochloride Formulation Dosed at 
Bedtime Compared to Placebo and to Morning Dosing 
in Chronic Stable Angina Pectoris 
SteDhen P. Glasser, Theophilus J. Gana, Luz G. Pascual, Kenneth S. Albert, University 
of Minnesota, Minneapolis, MN, Biovail Corporation, Chantilly, VA 
Background: The efkcacy and Safety of a chronotherapeutic graded-release diltiazem 
HCI formulation (GRD) dosed once-daily at 10 PM in doses of 160, 360 and 420 mg were 
evaluated in a 3-week multi-center. randomized, double-blind, parallel group trial by com- 
parison to placebo and to GRD 360 mg dosed once-daily at 8 AM in patients (n=311) with 
chronic stable angina pectoris. 
Methods: Standard Bruce protocol treadmill stress test was performed at baseline and 
endpoint, between 6 - 8 PM (trough for PM doses) and between 7 - 11 AM (trough for 
AM doses). Efficacy variables were change from baseline in total duration of exercise 
(primary); and time to onset of angina and time to21 mm ST segment depression (sec- 
ondary variables). 
Results: All PM doses of GRD showed a significant (~~0.03) increase in the total dura- 
tion of exercise at trough compared to placebo, with the 360 PM dose showing the great- 
est increase. In contrast, GRD 360 AM showed an increase in the total duration of 
exercise at trough that was not significant (p=O.O6) compared to placebo AM. Between 7 
- 11 AM, all PM doses showed significantly greater increase (fZO.0902) in the total dura- 
tion of exercise versus placebo. GRD 360 PM showed a 4-fold improvement over pla- 
cebo compared to GRD 360 AM. Time to onset of angina was srgnificantly increased for 
all GRD PM doses compared to placebo between 6 - 8 PM (~~0.02) and between 7 - 11 
AM (p<O.O3). Only the 360 PM dose showed a significant (~~0.03) increase in time to 
onset of myocardial &hernia between 6 - 8 PM, but between 7 - 11 AM all GRD PM 
doses showed a significant increase compared to placebo (~~0.03). Overall. the inci- 
dence of adverse events (AEs) for all GRD groups combtned (42.4%) was less than that 
obtained for the placebo group (47.5%). Improvement in exercise tolerance from 180 to 
360 PM occurred without ah associated increase in AEs compared to placebo. 
Conclusion: Bedtime GRD significantly increased exercise tolerance in patients with 
angina pectoris over the 24.hour dosing interval. A greater 4-fold improvement versus 
placebo in exercrse tolerance occurred between 7 - 11 AM for the PM dose compared to 
the same AM dose, coinciding with the period of clustering of cardiovascular events. 
GAD was safe and very well tolerated. 
1026-l 03 Aspirin Resistance in Patients With Coronary Artery 
Disease 
Brran L. Wahoo Andrew B. Civitello. James M. Wilson, Paul Allison, Arthur Bracey. 
James J. Ferguson, St. Luke’s Episcopal Hospital/Texas Head Institute. Houston, TX 
Background:Standard of care for the treatment of patients with coronary artery disease 
(CAD) includes antiplatelet therapy with aspirin (ASA). However, the antiplatelet effect of 
ASA varies across the broad distribution of CAD patients. Aspirin resistance refers to a 
cohort of patients that do not achieve significant inhibition of platelet aggregation with 
ASA therapy. Assessment of the true prevalence of aspirin resistance is complicated by 
lack of a uniform definition; moreover, the clinical implications ASA resistance is 
unknown. This study evaluates the prevalence of aspirin resistance and the spectrum of 
responsiveness to ASA therapy. 
Methods: Patients with CAD who were treated with aspirin (81-325 mg) for sew?” con- 
secutive days underwent platelet aggregometry (PA). Standard PA using 0.5 mglml 
arachidonic acid (AA) and 1 x lti M epinephrine (EPI) as agonists was performed and 
reported es percentage aggregation. Normal thresholds for platelet responsiveness with- 
out ASA were defined as 48% aggregation for EPI and 63 % aggregation for AA. 
Results: 48 patients including 6 (12.5%) females and 42 (87.5%) males were studied. 
One patient (2%) was overtly aspirin resistant, defined as abnormal response to both 
agonists. 8 patients (16.7%) demonstrated partial response to ASA, with ah abnormal 
response to one agonist and a normal response to the other agonist. 
Conclusion:A significant portion of patients (18.8%) with CAD have complete or partial 
resistance to ASA therapy using platelet aggregometry 
